New ETF Tracks Developers of Obesity Drugs Amid Ozempic Hype

A niche issuer is launching a biotechnology exchange-traded fund whose key holdings include firms benefiting from the hype around weight-loss drugs.

The Tema Cardiovascular and Metabolic ETF (ticker HRTS) tracks companies involved in the treatment of cardio-metabolic diseases — a term that links cardiovascular diseases, obesity and diabetes. The ETF, which has a novel investing mandate in the world of thematic allocations, charges a 0.75% management fee.

The actively managed fund has 20 to 25 core positions, including Eli Lilly & Co. and Novo Nordisk A/S, as well as Arrowhead Pharmaceuticals Inc. and Bridgebio Pharma Inc., said Maurits ...